Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Bio-Techne Corp (TECH) AI Forecast

Our AI analyzed Bio-Techne Corp. Create a free account and follow it to see the 90-day price prediction.

Free account • 30-day free trial

$TECH Neutral Signal Full forecast available

Bio-Techne Corp (TECH) Stock Forecast 2025


Bio-Techne Corp (TECH) AI Stock Price Forecast & Investment Analysis

Bio-Techne Corp Stock Price Chart and Technical Analysis

Loading chart...

Bio-Techne Corp (TECH) - Comprehensive Stock Analysis & Investment Research

Deep dive into Bio-Techne Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 2:56 p.m. (UTC)

Bio-Techne Corp Investment Summary

When evaluating whether Bio-Techne Corp (TECH) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Bio-Techne Corp (TECH) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $11 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Bio-Techne Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Bio-Techne Corp along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Bio-Techne Corp is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Bio-Techne Corp

Sign Up Free
Corporate Identity

Bio-Techne Corp (Stock Symbol: TECH) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Bio-Techne Corp's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Bio-Techne Corp...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Bio-Techne Corp...

Unlock Full Company Profile

Get complete details about Bio-Techne Corp

Sign Up Free
Revenue & Growth Analysis

Bio-Techne Corp generates annual revenues of $1 billion , indicating a well-established business with proven market demand.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Bio-Techne Corp...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Bio-Techne Corp...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Bio-Techne Corp...

Unlock Financial Analysis

Get complete financial metrics for Bio-Techne Corp

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Bio-Techne Corp's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Bio-Techne Corp strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Bio-Techne Corp competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $270 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Margin & Pricing Power Analysis

The company maintains a 77.6% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of 56.5% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This strong operating margin indicates excellent cost control and efficient organizational structure relative to the revenue base.

Asset Utilization Efficiency

Asset turnover ratio of 0.47x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 4.49 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Bio-Techne Corp (TECH) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Bio-Techne Corp stock analysis.

Deep dive into Bio-Techne Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Bio-Techne Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Bio-Techne Corp: With a P/E ratio of 102.53, the market highly values future growth prospects.

P/E Ratio 102.53x
P/B Ratio 5.39x
Market Cap $11.23B
Dividend Yield 0.44%
EPS $0.71
Book Value/Share $13.32
Revenue/Share $7.74
FCF/Share $1.72
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Bio-Techne Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Bio-Techne Corp: An ROE of 5.1% indicates room for improvement in shareholder value creation.

ROE 5.1%
ROA 4.1%
ROIC 6.4%
Gross Margin 77.6%
Operating Margin 56.5%
Net Margin 38.8%
EBT Margin 56.5%
Tax Rate 32.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Bio-Techne Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Bio-Techne Corp: A current ratio of 4.49 indicates strong liquidity.

Current Ratio 4.49x
Quick Ratio 3.18x
Financial Leverage 1.22x
Interest Coverage 25.3x
Working Capital $535M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Bio-Techne Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Bio-Techne Corp: Free cash flow of $270M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $123M
Free Cash Flow $270M
Capital Spending $147M
FCF/Sales 22.3%
CapEx/Sales 12.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Bio-Techne Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Bio-Techne Corp: An asset turnover of 0.47x suggests room for improvement in asset utilization.

Asset Turnover 0.47x
Receivables Turnover 5.6x
Inventory Turnover 0.3x
Fixed Assets Turnover 5.2x
Days Sales Outstanding 65 days
Days Inventory 1204 days
Payables Period 141 days
Cash Conversion Cycle 1129 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Bio-Techne Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Bio-Techne Corp: With annual revenue of $1210M, Bio-Techne Corp operates at significant scale.

Income Statement
Total Revenue $1.21B
Operating Income $153M
Net Income $105M
R&D Expense $26M
SG&A Expense $30M
Cost of Goods Sold $61M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 688%
Cash & Short-term Investments 210%
Short-term Debt 130%
Accounts Receivable 215%
Inventory 201%
Dividend & Shareholder Information
Dividends Per Share $0.32
Shares Outstanding 157M
Growth Metrics (YoY)
Net Income Growth 38.8%
EPS Growth 1.0%

Latest Bio-Techne Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Bio-Techne Corp (TECH) stock price and investment outlook.

📰 Loading...

Bio-Techne Corp Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Bio-Techne Corp against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $27M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $18M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $488M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Bio-Techne Corp Stock Forecast

How accurate are Bio-Techne Corp stock predictions?

Our AI model shows a -11% Spearman correlation coefficient for TECH predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Bio-Techne Corp stock price forecasts?

Our analysis considers Bio-Techne Corp's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Bio-Techne Corp a good investment in 2025?

Based on our AI analysis, Bio-Techne Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Bio-Techne Corp forecasts updated?

Bio-Techne Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Bio-Techne Corp?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...